Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17608925 | 0.95 | CHRM2 (0.60) | MGLLCHRM2CHRM3CYP2D6 | |
| SCHEMBL19325426 | 0.94 | MGLL (0.52) | MGLLCHRM2CHRM3OPRD1OPRK1 | |
| SCHEMBL17324842 | 0.90 | MGLL (0.70) | MGLLCHRM2CHRM3OPRD1OPRK1 | |
| SCHEMBL18785460 | 0.88 | MGLL (0.58) | MGLLCHRM2CHRM3OPRD1OPRK1 | |
| SCHEMBL30869854 | 0.85 | MEN1 (0.52) | MGLLCHRM2CHRM3OPRD1OPRK1 | |
| SCHEMBL2821181 | 0.82 | MEN1 (0.54) | MGLLCHRM2CHRM3OPRD1OPRK1 | |
| SCHEMBL25630988 | 0.82 | MGLL (0.44) | MGLLCHRM2CHRM3OPRD1OPRK1 | |
| SCHEMBL17325115 | 0.81 | MGLL (0.53) | MGLLOPRD1OPRK1CYP2D6CYP3A4 | |
| SCHEMBL17619563 | 0.81 | CYP2D6 (0.46) | MGLLCHRM2CHRM3OPRD1OPRK1 | |
| SCHEMBL1426231 | 0.81 | CYP2D6 (0.64) | CYP2D6CYP3A4TSHRCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129104-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| EP-4058439-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003659-A | 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity | 健赞公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021097057-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
| US-9908897-B2 | Spirocyclic derivatives | CHRONOS THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| EP-3201195-A1 | SPIROCYCLIC DERIVATIVES | Chronos Therapeutics Limited (GB) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016042452-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
| EP-1515965-B1 | PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | MGLL 2136/4885CHRM2 4083/4885CHRM3 3545/4885 |
| US-20170253615-A1 | Spirocyclic derivatives | SLC6A3, SLC10A1, ABCB11 | MGLL 1357/4885CHRM2 195/4885CHRM3 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.